BACKGROUND: Cerebral edema (CED) deteriorates outcome of ischemic stroke patients, and there is no effective medical treatment. Limited data exist on cerebral edema after stroke thrombolysis. AIMS: We aimed to analyze impact of cerebral edema on the outcome of thrombolysis-treated patients. METHODS: Our cohort included 943 thrombolysis-treated ischemic stroke patients at the Helsinki University Central Hospital (1995-2008). Cerebral edema represented focal brain swelling up to 1/3 (CED-1) or greater than 1/3 (CED-2) of the hemisphere, or midline shift (CED-3). We studied baseline parameters associated with development of cerebral edema and association of cerebral edema with three-month outcome (modified Rankin Scale, mRS). RESULTS: On control imaging, CED-1 was present in 167 (17·7%), CED-2 in 40 (4·2%), and CED-3 in 53 (5·6%) patients. Compared with patients without edema (n = 683), patients with cerebral edema had higher baseline National Institutes of Health Stroke Scale scores, more often hyperdense cerebral artery sign or early infarct signs on admission computerized tomography, and received thrombolysis later. Cerebral edema was independently associated with poor outcome (mRS 3-6) and mortality, whereas favorable outcome (mRS 0-2) was observed in 77 (46%), 5 (13%), and 3 (6%) patients with CED 1, 2, and 3, respectively. Anti-edema treatment was considered necessary and administered to 49/260 (19%) patients; only five had favorable outcome. CONCLUSIONS: Cerebral edema is frequent (28%) among thrombolysis-treated ischemic stroke patients, occurring in severe forms in 10%. Higher baseline National Institutes of Health Stroke Scale, presence of hyperdense cerebral artery sign or early infarct signs, and longer treatment delays are associated with edema development. Edema is a strong independent predictor of three-month outcome. Effect of anti-edema treatment was modest.
BACKGROUND:Cerebral edema (CED) deteriorates outcome of ischemic strokepatients, and there is no effective medical treatment. Limited data exist on cerebral edema after stroke thrombolysis. AIMS: We aimed to analyze impact of cerebral edema on the outcome of thrombolysis-treatedpatients. METHODS: Our cohort included 943 thrombolysis-treated ischemic strokepatients at the Helsinki University Central Hospital (1995-2008). Cerebral edema represented focal brain swelling up to 1/3 (CED-1) or greater than 1/3 (CED-2) of the hemisphere, or midline shift (CED-3). We studied baseline parameters associated with development of cerebral edema and association of cerebral edema with three-month outcome (modified Rankin Scale, mRS). RESULTS: On control imaging, CED-1 was present in 167 (17·7%), CED-2 in 40 (4·2%), and CED-3 in 53 (5·6%) patients. Compared with patients without edema (n = 683), patients with cerebral edema had higher baseline National Institutes of Health Stroke Scale scores, more often hyperdense cerebral artery sign or early infarct signs on admission computerized tomography, and received thrombolysis later. Cerebral edema was independently associated with poor outcome (mRS 3-6) and mortality, whereas favorable outcome (mRS 0-2) was observed in 77 (46%), 5 (13%), and 3 (6%) patients with CED 1, 2, and 3, respectively. Anti-edema treatment was considered necessary and administered to 49/260 (19%) patients; only five had favorable outcome. CONCLUSIONS:Cerebral edema is frequent (28%) among thrombolysis-treated ischemic strokepatients, occurring in severe forms in 10%. Higher baseline National Institutes of Health Stroke Scale, presence of hyperdense cerebral artery sign or early infarct signs, and longer treatment delays are associated with edema development. Edema is a strong independent predictor of three-month outcome. Effect of anti-edema treatment was modest.
Authors: Manuel Cappellari; Gianni Turcato; Massimo Zannoni; Stefano Forlivesi; Antonio Maccagnani; Antonio Bonora; Giorgio Ricci; Gian Luca Salvagno; Gianfranco Cervellin; Bruno Bonetti; Giuseppe Lippi Journal: J Thromb Thrombolysis Date: 2018-02 Impact factor: 2.300
Authors: Antonio Muscari; Luca Faccioli; Maria Vittoria Lega; Andrea Lorusso; Marco Pastore Trossello; Giovanni M Puddu; Luca Spinardi; Marco Zoli Journal: Neurol Sci Date: 2019-01-19 Impact factor: 3.307
Authors: Rajat Dhar; Yasheng Chen; Ali Hamzehloo; Atul Kumar; Laura Heitsch; June He; Ling Chen; Agnieszka Slowik; Daniel Strbian; Jin-Moo Lee Journal: Stroke Date: 2019-12-10 Impact factor: 7.914
Authors: Rajat Dhar; Ali Hamzehloo; Atul Kumar; Yasheng Chen; June He; Laura Heitsch; Agnieszka Slowik; Daniel Strbian; Jin-Moo Lee Journal: J Cereb Blood Flow Metab Date: 2021-05-20 Impact factor: 6.200
Authors: Felix C Ng; Leonid Churilov; Nawaf Yassi; Timothy J Kleinig; Vincent Thijs; Teddy Y Wu; Darshan Shah; Helen M Dewey; Gagan Sharma; Patricia M Desmond; Bernard Yan; Mark W Parsons; Geoffrey A Donnan; Stephen M Davis; Peter J Mitchell; Bruce Cv Campbell Journal: J Cereb Blood Flow Metab Date: 2021-05-17 Impact factor: 6.200
Authors: Simiao Wu; Grant Mair; Geoff Cohen; Zoe Morris; Anders von Heijne; Nick Bradey; Lesley Cala; Andre Peeters; Andrew J Farrall; Alessandro Adami; Gillian Potter; Ming Liu; Richard I Lindley; Peter A G Sandercock; Joanna M Wardlaw Journal: Stroke Vasc Neurol Date: 2020-11-27